MPT0G211 mesylate

MPT0G211 mesylate 是一种高效、口服活性且选择性的 HDAC6 抑制剂(IC50=0.291 nM),对 HDAC6 的选择性是其他 HDAC 亚型的 1000 倍,可透过血脑屏障,能改善阿尔茨海默病模型中的 tau 磷酸化和认知缺陷,具有抗转移、神经保护及抗癌活性。
产品编号: MS-T57803 CAS No.: 2151854-33-8 分子式: C18H19N3O5S 分子量: 389.43
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MPT0G211 mesylate 是一种高效、口服活性且选择性的 HDAC6 抑制剂(IC50=0.291 nM),对 HDAC6 的选择性是其他 HDAC 亚型的 1000 倍,可透过血脑屏障,能改善阿尔茨海默病模型中的 tau 磷酸化和认知缺陷,具有抗转移、神经保护及抗癌活性。

生物实验数据

生物活性 MPT0G211 mesylate is a potent, orally active and selective HDAC6 inhibitor (IC50=0.291 nM) that is 1000-fold selective for HDAC6 over other HDAC isoforms, crosses the blood-brain barrier, ameliorates tau phosphorylation and cognitive deficits in Alzheimer's disease models, and exhibits anti-metastatic, neuroprotective and anticancer activities.
IC50 & Target HDAC6:0.291 μM
体外研究
(In Vitro)

MPT0G211 mesylate (0.1 μM; Cells were transfected with pCAX APP 695 and pRK5-EGFP-Tau P301L for 24 h) significantly inhibited the phosphorylation of tau Ser396.
MPT0G211 mesylate inhibits HDAC6/Hsp90 binding and causes subsequent proteasomal degradation of polyubiquitinated proteins.
MPT0G211 mesylate significantly decreases the phosphorylation of tau by GSK3β inactivation.
MPT0G211 mesylate (0.1 μM; 24 hours) significantly attenuates the phosphorylation of tau Ser396 and Ser404 in both cell lines (SH-SY5Y and Neuro-2a cells were transfected for 24 h with pCAX APP 695 and pRK5-EGFP-Tau P301L).
MPT0G211 mesylate inhibits MDA-MB-231 and MCF-7 cells growth (GI50=16.19 and 5.6 μM, respectively).
In AML cells, MPT0G211 mesylate potentiates the cytotoxic effects of DOXO by impairing DNA repair machinery and activating Bcl-2-associated X protein (BCL-XL)-dependent cell apoptosis.

体内研究
(In Vivo)

MPT0G211 mesylate (50 mg/kg; p.o.; daily for 3 months) significantly ameliorates the spatial memory impairment.
MPT0G211 mesylate (25 mg/kg; i.p.; qd; day 73 post-tumor injection) reduces numbers of nodules and lung weights.
MPT0G211 mesylate treatment not only diminishes tau phosphorylation by inhibition GSK3β activity but also enhances the acetylation of Hsp90, which causes the downregulation of HDAC6/Hsp90 binding and facilitates proteasomal degradation of polyubiquitinated p-tau.

Animal Model: Triple transgenic (3×Tg-AD) mice (harboring APPSwe and tauP301L mutant transgenes
Dosage: 50 mg/kg
Administration: P.o.; daily for 3 months
Result: Significantly ameliorated the spatial memory impairment.
Animal Model: Female SCID mice (bearing MDA-MB-231 cells)
Dosage: 25 mg/kg
Administration: I.p.; qd; day 73 post-tumor injection
Result: Significantly reduced numbers of nodules and lung weights.

化学信息

分子量 389.43
分子式 C18H19N3O5S
CAS No. 2151854-33-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础